Benitec Biopharma Ltd Stock Piotroski F Score
| BNTC Stock | USD 10.15 0.34 3.24% |
Benitec | Piotroski F Score |
At this time, it appears that Benitec Biopharma's Piotroski F Score is Poor. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
4.0
Piotroski F Score - Poor
| Current Return On Assets | Negative |
| Change in Return on Assets | Decreased |
| Cash Flow Return on Assets | Negative |
| Current Quality of Earnings (accrual) | Improving |
| Asset Turnover Growth | Decrease |
| Current Ratio Change | Increase |
| Long Term Debt Over Assets Change | N/A |
| Change In Outstending Shares | Increase |
| Change in Gross Margin | Increase |
Benitec Biopharma Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to Benitec Biopharma is to make sure Benitec is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Benitec Biopharma's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Benitec Biopharma's financial numbers are properly reported.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0039 | 0.0041 |
|
| |||||
| Total Current Liabilities | 5.2 M | 4.9 M |
|
| |||||
| Total Assets | 54.8 M | 52.2 M |
|
| |||||
| Total Current Assets | 54.3 M | 51.7 M |
|
|
Benitec Biopharma F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Benitec Biopharma's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Benitec Biopharma in a much-optimized way.
Click cells to compare fundamentals
About Benitec Biopharma Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.Book Value Per Share |
|
Benitec Biopharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Benitec Biopharma from analyzing Benitec Biopharma's financial statements. These drivers represent accounts that assess Benitec Biopharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Benitec Biopharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 8.1M | 18.3M | 9.5M | 5.6M | 29.5M | 33.0M | |
| Enterprise Value | (1.3M) | (1.3M) | 6.2M | 3.7M | (21.1M) | (20.0M) |
Benitec Biopharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Benitec Biopharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Benitec Biopharma's managers, analysts, and investors.Environmental | Governance | Social |
About Benitec Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Benitec Biopharma Ltd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Benitec Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Benitec Biopharma Ltd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Benitec Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Benitec Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Benitec Biopharma Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Benitec Biopharma Ltd Stock:Check out Benitec Biopharma Altman Z Score, Benitec Biopharma Correlation, Benitec Biopharma Valuation, as well as analyze Benitec Biopharma Alpha and Beta and Benitec Biopharma Hype Analysis. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Benitec Biopharma. If investors know Benitec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Benitec Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.51) | Revenue Per Share 0.003 | Quarterly Revenue Growth 0.125 | Return On Assets (0.50) | Return On Equity (0.92) |
The market value of Benitec Biopharma is measured differently than its book value, which is the value of Benitec that is recorded on the company's balance sheet. Investors also form their own opinion of Benitec Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Benitec Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Benitec Biopharma's market value can be influenced by many factors that don't directly affect Benitec Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Benitec Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Benitec Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Benitec Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.